JP2017520531A5 - - Google Patents

Download PDF

Info

Publication number
JP2017520531A5
JP2017520531A5 JP2016568950A JP2016568950A JP2017520531A5 JP 2017520531 A5 JP2017520531 A5 JP 2017520531A5 JP 2016568950 A JP2016568950 A JP 2016568950A JP 2016568950 A JP2016568950 A JP 2016568950A JP 2017520531 A5 JP2017520531 A5 JP 2017520531A5
Authority
JP
Japan
Prior art keywords
fragment
antibody
hydrophobic interaction
interaction chromatography
ultrafiltration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016568950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017520531A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/001643 external-priority patent/WO2015186004A2/en
Publication of JP2017520531A publication Critical patent/JP2017520531A/ja
Publication of JP2017520531A5 publication Critical patent/JP2017520531A5/ja
Pending legal-status Critical Current

Links

JP2016568950A 2014-06-02 2015-06-02 Fc断片の産生 Pending JP2017520531A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462006584P 2014-06-02 2014-06-02
US62/006,584 2014-06-02
PCT/IB2015/001643 WO2015186004A2 (en) 2014-06-02 2015-06-02 Production of fc fragments

Publications (2)

Publication Number Publication Date
JP2017520531A JP2017520531A (ja) 2017-07-27
JP2017520531A5 true JP2017520531A5 (enExample) 2018-07-12

Family

ID=54337822

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016568950A Pending JP2017520531A (ja) 2014-06-02 2015-06-02 Fc断片の産生

Country Status (12)

Country Link
US (1) US20170129966A1 (enExample)
EP (1) EP3149030A2 (enExample)
JP (1) JP2017520531A (enExample)
KR (1) KR20170040132A (enExample)
CN (1) CN106573973A (enExample)
AR (1) AR100716A1 (enExample)
AU (1) AU2015270152A1 (enExample)
BR (1) BR112016028182A2 (enExample)
CA (1) CA2950241A1 (enExample)
IL (1) IL249274A0 (enExample)
MX (1) MX2016015893A (enExample)
WO (1) WO2015186004A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011350895B2 (en) 2010-12-30 2015-05-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Glycols as pathogen inactivating agents
BR112015019348A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
MX384222B (es) 2013-07-05 2025-03-14 Lab Francais Du Fractionnement Matriz de cromatografia de afinidad.
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
US11618769B2 (en) 2017-11-14 2023-04-04 Bio-Sourcing S.A. Antibody purification
FR3075200B1 (fr) * 2017-12-15 2022-12-23 Lab Francais Du Fractionnement Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
WO2019116096A1 (en) * 2017-12-15 2019-06-20 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Production of fc fragments
CN119881293A (zh) 2018-03-21 2025-04-25 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
CN110669134A (zh) * 2019-10-15 2020-01-10 广东菲鹏生物有限公司 IgM-FC片段、IgM-FC抗体及制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US6268487B1 (en) * 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
TW200740839A (en) * 2005-06-17 2007-11-01 Wyeth Corp Methods of purifying Fc region containing proteins
EP2815768A3 (en) * 2006-04-05 2015-01-14 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2662449B1 (en) 2007-05-30 2017-02-15 Postech Academy-Industry- Foundation Immunoglobulin fusion proteins
US20080311119A1 (en) * 2007-06-14 2008-12-18 Biogen Idec Ma Inc. Antibody formulations
RU2012133148A (ru) 2010-01-11 2014-02-20 Хилор Лтд. Способ лечения воспалительного заболевания и расстройства
CN104168913A (zh) * 2011-08-10 2014-11-26 法国化学与生物科技实验室 高半乳糖基化抗体
GB201115665D0 (en) 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy

Similar Documents

Publication Publication Date Title
JP2017520531A5 (enExample)
Klein et al. Engineering therapeutic bispecific antibodies using CrossMab technology
RU2016115866A (ru) Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
TWI455947B (zh) 拮抗性對抗人的cd40單株抗體
MX2022001831A (es) Anticuerpos terapeuticos y sus usos.
JP2015529236A5 (enExample)
HK1254357A1 (zh) 特异性针对过度磷酸化t蛋白的抗体及其使用方法
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
WO2012006596A3 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
JP2016530533A5 (enExample)
PE20220392A1 (es) Moleculas de union a claudina-6 y usos de las mismas
EP2522724A4 (en) POLYPEPTIDE MODIFYING METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
BR112015018203A2 (pt) Anti-corpos biespecíficos anti-tnf-anti-il-17
EP3564259A3 (en) Recognition tags for tgase-mediated conjugation
WO2013177115A3 (en) Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
JP2012116856A5 (enExample)
WO2017015619A8 (en) Antibodies to coagulation factor xia and uses thereof
JP2018505681A5 (enExample)
PE20191548A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
AR099625A1 (es) Anticuerpos de il-21
JP2016520595A5 (enExample)
JP2017505620A5 (enExample)
RU2019111862A (ru) Новые антитела против фактора xi и их применения
EA202192907A1 (ru) Моноклональное антитело, которое специфически связывается с gitr
JP2013539962A5 (enExample)